Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the progress and future directions in CAR T-cell therapy for the treatment of B-cell malignancies. The availability of CAR-T has altered the current treatment algorithm for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Indications will likely expand to other disease entities and earlier lines of therapy. Future directions include products targeting multiple tumor antigens to overcome resistance. This interview took place during the 3rd European CAR T-cell Meeting.
Grant, personal fees, and nonfinancial support from Novartis, Bristol Myers Squibb/Celgene, Gilead, Janssen, Merck, and Roche Grant and personal fees from Sanofi Personal fees and nonfinancial support from AbbVie, Amgen, AOP Orphan, Miltenyi Biotec, Sandoz, and Takeda